Nomogram-based prognostic stratification for resectable gastric signet-ring cell carcinoma and adenocarcinoma: A retrospective cohort study

Table 1 Patients and tumors’ clinical and pathological characteristics before and after propensity score matching, n (%)

Variable	All patients		P value	Matched patients		P value
	GA (n = 2151)	GSRCC (n = 886)		GA (n = 761)	GSRCC (n = 761)
Age (year)			< 0.001			0.382
< 60	939 (43.65)	540 (60.95)		404 (53.09)	422 (55.45)
≥ 60	1212 (56.35)	346 (39.05)		357 (46.91)	339 (44.55)
Gender			< 0.001			0.510
Male	1717 (79.82)	576 (65.01)		524 (68.86)	511 (67.15)
Female	434 (20.18)	310 (34.99)		237 (31.14)	250 (32.85)
BMI (kg/m2)			0.347			0.644
< 24	1099 (51.09)	470 (53.05)		407 (53.48)	397 (52.17)
≥ 24	1052 (48.91)	416 (46.95)		354 (46.52)	364 (47.83)
Comorbidity (yes)	906 (42.12)	341 (38.49)	0.070	332 (43.63)	306 (40.21)	0.194
Smoking history (yes)	1099 (51.09)	369 (41.65)	< 0.001	342 (44.94)	322 (42.31)	0.326
Drinking history (yes)	1010 (46.95)	383 (43.23)	0.067	334 (43.89)	335 (44.02)	1.000
Tumor location			< 0.001			0.449
Upper	859 (39.93)	171 (19.30)		190 (24.97)	171 (22.47)
Middle	411 (19.11)	231 (26.07)		183 (24.05)	208 (27.33)
Lower	841 (39.10)	443 (50.00)		357 (46.91)	351 (46.12)
More than two position or total	40 (1.86)	41 (4.63)		31 (4.07)	31 (4.07)
Differentiation			< 0.001			0.932
Poor	784 (36.45)	717 (80.93)		598 (78.58)	592 (77.79)
Moderate	1228 (57.09)	167 (18.85)		161 (21.16)	167 (21.94)
Well	139 (6.46)	2 (0.23)		2 (0.26)	2 (0.26)
Size (cm)			< 0.001			0.196
1 < 4	904 (42.03)	435 (49.10)		319 (41.92)	345 (45.34)
2 ≥ 4	1247 (57.97)	451 (50.90)		442 (58.08)	416 (54.66)
Perineural invasion (yes)	1039 (48.30)	424 (47.86)	0.854	418 (54.93)	412 (54.14)	0.797
Vascular invasion (yes)	867 (40.31)	328 (37.02)	0.100	335 (44.02)	315 (41.39)	0.325
pT stage			< 0.001			0.955
T1	510 (23.71)	303 (34.20)		198 (26.02)	198 (26.02)
T2	309 (14.37)	107 (12.08)		99 (13.01)	100 (13.14)
T3	728 (33.84)	182 (20.54)		173 (22.73)	181 (23.78)
T4a/4b	604 (28.08)	294 (33.18)		291 (38.24)	282 (37.06)
pN stage			< 0.001			0.723
N0	848 (39.42)	377 (42.55)		264 (34.69)	275 (36.14)
N1	367 (17.06)	100 (11.29)		86 (11.30)	96 (12.61)
N2	375 (17.43)	145 (16.37)		144 (18.92)	136 (17.87)
N3	561 (26.08)	264 (29.80)		267 (35.09)	254 (33.38)
pTNM stage			< 0.001			0.115
I	632 (29.38)	317 (35.78)		219 (28.78)	213 (27.99)
II	558 (25.94)	175 (19.75)		135 (17.74)	167 (21.94)
III	961 (44.68)	394 (44.47)		407 (53.48)	381 (50.07)
Adjuvant chemotherapy (yes)	747 (34.73)	304 (34.31)	0.859	310 (40.74)	291 (38.24)	0.345

BMI: Body mass index; GA: Gastric adenocarcinoma; GSRCC: Gastric signet ring cell carcinoma; pTNM: Post-treatment nodal margin.